Disc Medicine COO sells 18,612 shares under plan

Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen reported option exercises and related share sales.

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen reported option exercises and related share sales. On June 16, 2026, he exercised stock options for a total of 18,612 shares of common stock at an exercise price of $9.86 per share and sold 18,612 shares in open-market transactions. The sales occurred at weighted average prices of about $68.76 and $69.92 per share, within ranges from $68.37 to $70.19. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Exercise and Sale: 18,612 shares ($1.10M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Yu Jonathan Yen-Wen

Role Chief Operating Officer

Sold 18,612 shs ($1.29M)

Approx. gross sale proceeds $1.29M

Approx. exercise cost $184K

Approx. pre-tax spread $1.10M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	5,261	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	13,351	$0.00	$0.00
Exercise	Common Stock	5,261	$9.86	$52K
Exercise	Common Stock	13,351	$9.86	$132K
Sale	Common Stock	11,651	$68.7582	$801K
Sale	Common Stock	6,961	$69.918	$487K

Holdings After Transaction: Stock Option (Right to Buy) — 33,704 contracts (Direct); Common Stock — 54,324 shares (Direct)

Footnotes (4)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 to $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.40 to $70.19, inclusive.
4. F4. The shares underlying this option are fully vested and exercisable as of the date hereof.

Key Figures

Shares sold (total): 18,612 shares Sale tranche 1: 11,651 shares at $68.7582 Sale tranche 2: 6,961 shares at $69.918 +3 more

6 metrics

Shares sold (total) 18,612 shares Common Stock open-market sales on June 16, 2026

Sale tranche 1 11,651 shares at $68.7582 Weighted average price; trades from $68.37 to $69.36

Sale tranche 2 6,961 shares at $69.918 Weighted average price; trades from $69.40 to $70.19

Options exercised (total) 18,612 shares Derivative exercises converting options into common stock

Option exercise price $9.86 per share Conversion or exercise price for Stock Option (Right to Buy)

10b5-1 plan adoption date March 17, 2026 Rule 10b5-1 trading plan governing June 16, 2026 trades

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Disc Medicine (IRON) report for its COO?

Disc Medicine reported that COO Yu Jonathan Yen-Wen exercised stock options and sold common shares. On June 16, 2026, he exercised options for 18,612 shares at $9.86 and sold 18,612 shares in open-market trades at weighted average prices in the high-$60 range.

How many Disc Medicine (IRON) shares did the COO sell and at what prices?

The COO sold a total of 18,612 Disc Medicine common shares. He sold 11,651 shares at a weighted average price of $68.7582 and 6,961 shares at $69.918, with actual trade prices ranging between $68.37 and $70.19 per share.

Did the Disc Medicine (IRON) COO exercise stock options in this Form 4 filing?

Yes. The filing shows the COO exercised stock options covering 13,351 shares and 5,261 shares of Disc Medicine common stock. Both option tranches had a conversion or exercise price of $9.86 per share, turning option awards into directly held common shares.

Were the Disc Medicine (IRON) insider share sales made under a 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. Such plans pre-schedule trades, indicating the timing of these June 16, 2026 sales was set in advance, not chosen opportunistically.

What does the weighted average price disclosure mean in this Disc Medicine Form 4?

The Form 4 notes that the reported prices are weighted averages for multiple trades. Shares were sold in numerous individual transactions within specified price ranges, and the insider offers to provide exact share counts at each price to the issuer, shareholders, or SEC staff upon request.

What type of derivative securities did the Disc Medicine (IRON) COO exercise?

He exercised “Stock Option (Right to Buy)” derivatives linked to Disc Medicine common stock. Two option lines covered 13,351 and 5,261 underlying shares, each with a $9.86 exercise price, and the filing notes the underlying shares were fully vested and exercisable as of the transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jonathan Yen-Wen

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		M(1)		5,261	A	$9.86	59,585	D
Common Stock	06/16/2026		M(1)		13,351	A	$9.86	72,936	D
Common Stock	06/16/2026		S(1)		11,651	D	$68.7582(2)	61,285	D
Common Stock	06/16/2026		S(1)		6,961	D	$69.918(3)	54,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.86	06/16/2026		M(1)			5,261	(4)	09/13/2031	Common Stock	5,261	$0	1,753	D
Stock Option (Right to Buy)	$9.86	06/16/2026		M(1)			13,351	(4)	09/13/2031	Common Stock	13,351	$0	31,951	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 to $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.40 to $70.19, inclusive.

4. The shares underlying this option are fully vested and exercisable as of the date hereof.

	By: /s/ Rahul Khara, as Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)